All In Biotech

Drug Trial Radar · NCT01268358

Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.

Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Oct 2010

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
Zymenex A/SIndustry
Sponsor type
Industry
Collaborators
European Commission
First posted
Dec 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of Lamazym. In order to avoid development of delayed hypersensitivity all patients will continue weekly treatment at the designated dose until the Safety Committee approves transfer to the rhLAMAN-03 protocol. It is the hypothesis that Lamazym is safe to use.

Conditions

  • Alpha Mannosidosis

Interventions

  • LamazymDrug

    Lamazym, ERT, infusion weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety profile of rhLAMAN (Lamazym)Time frame: 1-5 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.